Helping mothers and babies, from conception to birth
At Ferring, we are committed to helping people become parents and to keeping mothers and babies healthy, from conception to birth. Over one third of our research and development investment goes towards finding innovative treatments in reproductive medicine and maternal health. We are also passionate about making a difference to people’s health and quality of life through our work in gastroenterology and urology.
Believing in the power of research
Each of us at Ferring contribute to providing innovative solutions to help people live better lives. We devote significant research and development investment to new therapeutics, life cycle management and next generation healthcare solutions.
At Ferring Pharmaceuticals we highly value an attractive working environment that motivates our employees and stimulates the creative abilities and initiative of both individuals and teams. With more than 7,000 employees in over 50 countries, we are able to draw upon a large multicultural setting to enrich the work of our staff on all levels.
Helping people live better lives
Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives. Ferring is a leader in reproductive medicine and maternal health, and in specialty areas within gastroenterology and urology. Ferring has been developing treatments for mothers and babies for over 50 years.
Four Analyses of Data for REBYOTA™ (fecal microbiota, live – jslm), the First FDA-Approved Microbiome-Based Treatment for the Prevention of Recurrent C. difficile Infection, Presented at DDW 2023-
Data presentations highlight Ferring’s microbiome leadership and commitment to ongoing research Analyses review safety and efficacy data across various patient…
Ferring and BioInnovation Institute enter new strategic collaboration to accelerate innovation in women’s health-
The new strategic collaboration will include supporting BioInnovation Institute (BII) to source and potentially fund early-stage start-ups and projects, specifically within the field of reproductive medicine This collaboration helps to fill a gap given…
Ferring announces abstract of the first prospective, multi-national, real-world study of Rekovelle® (follitropin delta) at the congress of the Pacific Society for Reproductive Medicine-
PROFILE is the first prospective, multi-national, observational, real-world study of Rekovelle in clinical practice, conducted in more than 940 women from 10 countries across…